QOP
RVNC

Quinn Opportunity Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Quinn Opportunity Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-110,113
Closed -$571K – 400
2024
Q3 		$571K Buy
110,113
+100,113
+1,001% +$498K 0.06% 187
2024
Q2 		$25.7K Hold
10,000
– – ﹤0.01% 277
2024
Q1 		$49.2K Hold
10,000
– – 0.01% 245
2023
Q4 		$87.9K Buy
+10,000
New +$81.9K 0.01% 219
2020
Q3 		– Sell
-15,200
Closed -$371K – 223
2020
Q2 		$371K Hold
15,200
– – 0.05% 142
2020
Q1 		$225K Sell
15,200
-41,572
-73% -$860K 0.03% 140
2019
Q4 		$921K Buy
56,772
+3,372
+6% +$52.3K 0.11% 98
2019
Q3 		$694K Buy
53,400
+728
+1% +$8.91K 0.08% 106
2019
Q2 		$683K Sell
52,672
-4,000
-7% -$50.4K 0.08% 111
2019
Q1 		$893K Hold
56,672
– – 0.12% 87
2018
Q4 		$1.14M Sell
56,672
-2,000
-3% -$44.1K 0.16% 66
2018
Q3 		$1.46M Buy
58,672
+25,572
+77% +$695K 0.21% 73
2018
Q2 		$909K Buy
33,100
+24,000
+264% +$721K 0.12% 98
2018
Q1 		$280K Hold
9,100
– – 0.04% 152
2017
Q4 		$325K Buy
+9,100
New +$261K 0.05% 139

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Quinn Opportunity Partners's RVNC Position: Q4 2024 in Review

Quinn Opportunity Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 110,113 shares — an estimated $571K sold.

Quinn Opportunity Partners first reported a position in RVNC in Q4 2017 and held it in 15 quarters. The position peaked at $1.46M in Q3 2018. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Quinn Opportunity Partners reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Quinn Opportunity Partners sold 110,113 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $571K.
  • Quinn Opportunity Partners first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 15 quarters.
  • Quinn Opportunity Partners's Revance Therapeutics, Inc. position peaked at $1.46M in Q3 2018.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Quinn Opportunity Partners's 13F filing for Q4 2024, filed 13 Feb 2025.